Results of this data analysis demonstrate the relationship between treatment facility volume and all-cause mortality among patients with multiple myeloma.
Data on neutropenia and infection-related complications in patients with ALL are lacking; therefore, this study focused on identifying the characteristics and risk factors of infection-related complications in children with newly diagnosed ALL.
This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.
Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.
Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.
Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.
In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.
[Blood and Lymphatic Cancer: Targets and Therapy] This research provides a summary of the pathobiology of polycythemia vera, and examines challenges associated with traditional PV treatment options and the clinical data for ruxolitinib.
High platelet counts and hemoglobin/hematocrit levels may be associated with hearing loss in patients with polycythemia vera.
Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML).
Infusion reactions during administration of high-dose carmustine as part of the BEAM conditioning regimen are common and do not appear to be reduced by modestly extending the duration of infusion or giving premedications.
There is a high incidence of severe acute and persistent cancer-related fatigue in survivors of Hodgkin lymphoma, regardless of tumor stage or treatment.
Daratumumab plus bortezomib and dexamethasone improves progression-free survival in multiple myeloma.
Daratumumab plus lenalidomide and dexamethasone resulted in rapid, deep, durable responses in patients with multiple myeloma.
Sociodemographic factors, not race or ethnicity, impact survival of younger patients with multiple myeloma.
Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).
For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.
Patients with acute myeloid leukemia (AML) harboring mutations in the TP53 gene have worse complete remission rates and durations and overall survival regardless of age or the type of treatment received.
Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
Researchers discovered that changes in the bone marrow needed for multiple myeloma to grow have already taken hold in patients with MGUS.
In a large cohort of hematologic oncologists surveyed in the United States, standard end-of-life quality measures were highly acceptable, but unrealistic patient expectations are the greatest impediment to quality end-of-life care.
In the era of tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation, the life expectancy of patients with CML is approaching that of the general population.
Lenalidomide is an effective treatment option with limited and reversible toxicities for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a 'real-world' study has shown.
Chimeric antigen receptor (CAR) T cell therapy is now moving toward effectiveness against solid tumors, based on recent work in mouse models. CAR T cell therapy has already had successes against aggressive blood cancers.
New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.
Incidence of frailty among young survivors of bone marrow transplant is similar to that of the elderly population, and increases the risk of death compared with nonfrail survivors.
Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Prolactin Expression May Indicate Better Prognosis for Patients With TNBC
- Caregiver Mastery Linked to Patient Survival in Glioblastoma
- Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma
- Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|